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Abstract
Objectives In children, there is often lack of sufficient information concerning
the pharmacokinetics (PK) and pharmacodynamics (PD) of a study drug to sup-
port dose selection and effective evaluation of efficacy in a randomised clinical
trial (RCT). Therefore, one should consider the relevance of relatively small
PKPD studies, which can provide the appropriate data to optimise the design of
an RCT.
Methods Based on the experience of experts collaborating in the EU-funded
Global Research in Paediatrics consortium, we aimed to inform clinician-scien-
tists working with children on the design of investigator-initiated PKPD studies.
Key findings The importance of the identification of an optimal dose for the
paediatric population is explained, followed by the differences and similarities of
dose-ranging and efficacy studies. The input of clinical pharmacologists with
modelling expertise is essential for an efficient dose-finding study.
Conclusions The emergence of new laboratory techniques and statistical tools
allows for the collection and analysis of sparse and unbalanced data, enabling the
implementation of (observational) PKPD studies in the paediatric clinic. Under-
standing of the principles and methods discussed in this study is essential to
improve the quality of paediatric PKPD investigations, and to prevent the con-
duct of paediatric RCTs that fail because of inadequate dosing.
It is unfortunate that a communication gap still exists
between paediatricians and clinical pharmacologists,
who can apply methodologies to validate current pre-
scription practice, in many cases without the need for
additional prospective trials. [1]
Introduction
Children have traditionally been protected from participa-
tion in medical (drug) research, and fas a consequence,
medications have not been appropriately labelled for
them.[2] Regulatory initiatives such as the Paediatric
Research Equity Act and Best Pharmaceuticals for
Children’s Act in the United States and the Paediatric
Regulation in the European Union (EU) provide incentives
for pharmaceutical companies to investigate new drugs in
children. Sponsors can submit a paediatric investigation
plan to support the authorisation of a new drug for chil-
dren.[3] However, off-label dosing recommendations for
currently marketed drugs need to be revisited,[1,4–8] espe-
cially for older, off-patent medications.[7] Given the general
lack of interest in the ‘paediatric-use marketing authorisa-
tion’ opportunity, which provides sponsors incentives for
research on off-patent drugs, the initiative to gather empiri-
cal evidence to support the dose rationale for older drugs is
left to non-commercial (academic) paediatric clinician-
scientists.[9] In fact, the need for increasing awareness of
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paediatricians about the value of investigator-initiated trials
in children is acknowledged in the revision of Directive of
the European Commission (EC) in 2014, which tries to
correct the bias towards trials sponsored by pharmaceutical
companies, ‘while those with non-commercial sponsors
were overlooked’.[10,11] Another element that has been
highlighted in the revised directive is the role of paediatric
networks to help consolidate available knowledge about
medicines and translate it into practice.[12,13] To meet the
demand for clinical trials, ‘the pediatric research enterprise
must act with diligence to address deficiencies in our cur-
rent preclinical and clinical research systems that often give
rise to irreproducible data. Historically, most federally
funded pediatric research programs were designed to gen-
erate data for publication rather than regulatory review, the
latter a standard that needs to withstand independent vali-
dation down to individual elements’.[13] Paediatric drug
research poses challenges, but innovations in trial design
and pharmacology prompt Rieder and Hawcutt[14] to con-
clude that ‘there has never been a better time for conduct-
ing drug studies in children’.
The general principles of randomised clinical trials
(RCTs) to study drug efficacy and effectiveness are well
known among most paediatricians. However, they may be
unaware that other types of studies, that is studies to iden-
tify the appropriate dose and dosing regimen in children,
might have a higher priority on the research agenda. Fail-
ure to perform these studies can lead to a negative trial
result, not because of insufficient statistical power (type II
error), but because of inadequate dose selection; that is,
the drug dose that is compared to placebo or another com-
parator results in too low exposure to ensure the required
clinical response in children. This was illustrated by a ret-
rospective investigation of the design aspects that might
have caused the failure of several antihypertensive dose–re-
sponse trials submitted to the Food and Drug Administra-
tion from 1998 to 2005.[15] The authors recommend that
‘future pediatric antihypertensive trials should incorporate
a wide range of doses and use information from adult trials
to account for potential pharmacological differences
between adult and pediatric populations’. As long as there
are no safety concerns, for dose–response trials these
authors advise to use a lowest dose that is lower than the
lowest approved relative dose (per kg or per m2) in adults,
and a highest relative dose that is at least twofold higher
than the highest approved relative dose in adults. We
would be more cautious and more specific about how to
evaluate a medicine, but we agree that characterisation of
the exposure–response curve requires the evaluation of
dose levels that result in a wide range of drug exposure,
including in some cases nominal dose levels that may be
lower or higher than the currently approved therapeutic
doses in adults.
This study aimed to close the communication gap
between clinical pharmacologists and paediatricians and
provide a starting point for the design of paediatric dose-
finding studies in such a way that the results can be used to
justify the dose rationale for children and consequently to
support the development of clinical guidelines and labelling
changes. We want to make clear (1) why the identification
of an optimal dose for the paediatric population is impor-
tant, (2) what the differences and similarities are in the
design and conduct between dose-ranging and efficacy
studies and (3) which information is needed for the plan-
ning of a dose-finding study and how this can be obtained.
Why the identification of an optimal dose
for the paediatric population is important
Many drugs used in daily paediatric practice lack a scientifi-
cally sound, evidence-based dosing regimen.[16,17] Off-label
doses in children are often the result of an extrapolation
exercise; that is, they are based on the adult dose corrected
only for differences in body size (e.g. body weight or body
surface area (BSA)). Such extrapolations often rely on the
assumption of a linear correlation between dose and size.
In fact, when using doses per kg or per square metre, one
implicitly assumes that fractioning of the dose will result in
comparable drug levels; that is, concentrations change in a
linear fashion with weight or BSA, respectively. This prac-
tice also assumes that children and adults are comparable
with regard to body composition and have similar gastroin-
testinal, renal and hepatic function (primary organs deter-
mining the absorption, distribution and metabolism of
drugs), as well as concentration–response relationships. As
developmental changes are mostly nonlinear, this so-called
empirical dosing can lead to over- or underdosing,
especially in specific age groups such as neonates and
(extremely) low-birthweight infants, thereby increasing the
risk of toxicity or reduced efficacy. The heterogeneity
within the paediatric population, ranging from very small
premature neonates to, sometimes overweight or obese,
18-year-olds, cannot be overemphasised.
To ensure that the aforementioned points are considered
for the selection of the dose and design of a clinical study, a
few basic concepts should be highlighted. Pharmacokinetics
(PK) describes what happens to a drug when it enters the
body (including absorption, distribution, metabolism and
excretion), and pharmacodynamics (PD) refers to the effect
the drug has on the body. Historically, a major constraint
for the evaluation of the dose rationale has been the lack of
information about drug exposure. Traditional PK studies
involve the collection of multiple blood samples in each
patient, usually taken according to a rigidly timed and
structured protocol, within a relatively small patient popu-
lation (e.g. n = 12). This ‘data-rich’ approach has severe
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limitations in paediatric practice for both ethical and prac-
tical reasons: the fixed sampling strategy potentially inter-
feres with patient care; and the requirement for multiple
blood samples (perhaps 12–15) raises concerns about
venous access and blood loss. Population PK (using sparse
sampling schemes in which less blood samples are taken
per individual without the need for a rigid sampling time
as compared to classical PK studies) and PKPD modelling
(using statistical models to characterise the exposure–re-
sponse relationship of a drug) are now well established.[18–23]
This approach prevents children being exposed to the prac-
tice of large numbers and volumes of blood sampling seen in
adult PK and PKPD studies.
Whereas the conduct of a PK study may suffice to sup-
port the dose rationale in some cases (e.g. when evidence
exists of comparable exposure–response relationships in
adults and children), clinicians and investigators are less
familiar with the requirements and conditions in which a
PKPD study is necessary. The criteria were initially set out
in a regulatory guidance, in which the FDA proposed a
‘paediatric study decision tree’.[24] This diagram shows the
requirements for using adult data (or any other reference
group or population) to extrapolate or infer efficacy and
safety in (specific groups of) children. Evidence that disease
progression, PKPD relationships and endpoints are similar
or comparable in both adults and children allows the use of
PK (bridging) studies to support the dose rationale for the
paediatric population. However, if these requirements are
not met, the decision tree clearly indicates the need for fur-
ther PKPD or efficacy studies. It is important to understand
that regulatory views in the European Union are slightly
different from those in the United States. According to a
reflection paper released by the European Medicines
Agency (EMA), extrapolation may be generally defined as:
‘Extending information and conclusions available from
studies in one or more subgroups of the patient population
(source population), or in related conditions or with
related medicinal products, to make inferences for another
subgroup of the population (target population), or condi-
tion or product, thus reducing the need to generate addi-
tional information (types of studies, design modifications,
number of patients required) to reach conclusions for the
target population, or condition or medicinal product’.
(EMA [25]: 2) Instead of a decision tree, the European reg-
ulators propose a framework to systematically determine
whether extrapolation can be applied, introducing the
requirement for an extrapolation plan and what such a plan
should entail.[26]
The creation of a framework for extrapolations has also
made explicit which are the requirements for data genera-
tion, in particular how studies should be designed following
the extrapolation plan, including the relevance of PKPD
and dose-ranging studies. The extrapolation plan represents
therefore a mechanism to ensure the accurate use of current
knowledge as well as the criteria for the use of biomarkers
and clinical endpoints, many of which have not been evalu-
ated or qualified to support a regulatory application. An
example of a study that has led to incorporation of the
starting dose and titration scheme (of argatroban) in the
US prescribing information is a study by Madabushi
et al.[27] An example of the use of a PD endpoint that has
been validated for use in children is the measurement of
pain in young children in De Cock et al.[28]
As these types of study have been an area of expertise
within pharmaceutical R&D, academic investigators still
have limited experience with their implementation. It
should therefore be clear that before performing a RCT, the
doses to be tested need to be selected and justified; other-
wise, trials may fail as has happened in the past.[15] Most
importantly, paediatricians need to understand that body
size (weight) is not necessarily a surrogate or proxy for dif-
ferences in physiological or organ function across the vari-
ous subgroups of the paediatric population. During the
planning and evaluation of the suitable dose(s) and dosing
regimens for children, different factors may need to be con-
sidered in an integrated manner, taking into account differ-
ences (as compared to adults) due to demographic and
clinical factors as well as the role of organ maturation,
ontogeny of enzymes and developmental growth.[29]
It is also worth mentioning that whereas maturation and
ontogeny play a critical role in very young children (e.g.
preterm newborns, term newborns, infants, toddlers), the
use of postnatal or even postmenstrual age does not neces-
sarily provide insight into organ function at an individual
patient level. For instance, one can use postmenstrual age
to refer to the average (patho)physiological difference in
glomerular filtration in preterm newborns, but one should
measure cystatin C to obtain accurate estimates of the
organ function in a given patient. In other words, the use
of age as a proxy or surrogate for function is of limited
value, given the large heterogeneity in organ maturation.[30]
Given the wide weight variation (see, e.g., quartiles of the
weight by age growth curves for male and female patients
from the World Health Organization and National Center
for Health Statistics[31,32]), the use of age as criterion for
dosing medicines in older children yields even larger errors.
Similarly, there is little scientific basis to support the use of
dosing based on BSA, as BSA does not accurately reflect dif-
ferences in organ or metabolic function. ‘Scaling for func-
tion’ is suggested[1] in which the dosing accounts for
developmental growth and different (patho)physiological
conditions.[24] BSA was introduced as a correction factor
for dosing regimens associated with poor tolerability, and
dates back to the introduction of cytotoxic medicines in
oncology. Current understanding of drug disposition and
PKPD relationships strongly suggests that weight- or
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biomarker-banded dosing regimens should be used if large
heterogeneity is anticipated in a given group of patients or
disease condition (e.g. renally impaired patients).
Differences and similarities in the design
and conduct between dose-finding and
efficacy studies
Dose-ranging studies, also known as phase II studies,
occupy a key position in clinical drug development. If
properly designed and accurately performed, a dose-finding
study will save time and effort during the assessment of effi-
cacy in comparative and large-scale trials in phase III.
Moreover, evidence from these studies may help to min-
imise the numbers of patients required in subsequent
phases of development or even eliminate the need for addi-
tional data.[33]
A key goal of phase II is to determine the effective dose
(s) that will inform a phase III trial. Often the results of
phase II studies will substantiate the dose and dosing regi-
men that will be used on the product label submitted for
approval as part of the new drug application. Whereas cur-
rent regulatory guidelines highlight the importance of iden-
tifying an effective and safe dose as the basis for approval of
a novel medicine, an overwhelming number of examples
show that the characterisation of the exposure–response
curve and subsequent selection of the optimal dose range
can have important implications for the development of
the medicinal product.[34] An optimal dose is a dose that is
high enough to demonstrate efficacy in the target popula-
tion taking into account the impact of variability in phar-
macokinetics and pharmacodynamics. Yet, this dose should
ensure minimum safety concerns and adverse events. There
are different strategies or approaches to determine the opti-
mal dose, and the three most common dose-finding study
designs are described below.
Parallel dose comparison
Parallel dose comparison studies are the classical dose-find-
ing studies.[35] This is still one of the most common (but
also the least efficient) study designs. In a parallel dose
comparison study, several potential doses are selected and
patients are randomised to receive one of the doses or pla-
cebo for the entire study period. At the end of the study,
the outcome in each treatment group is compared to the
placebo group. Given that these designs are not staggered,
all treatment groups, including the higher dose cohorts,
may be evaluated in parallel. Therefore, this study design is
best suited for situations where there is some confidence
about the location of the exposure–response curve and no
concern about the safety profile of the compound. On the
other hand, parallel dose comparisons are very inefficient
designs. They can make the identification of the optimal
dose and dosing regimen rather challenging if limited infor-
mation is available about the location of the dose–response
curve. Empirical choice of the doses to be used in a (paedi-
atric) study may lead to biased estimates of the parameters
describing the dose–response curve. Dose-finding parallel
group studies are difficult to perform in children due to the
relatively narrow dose range, the small interval between
tested doses, the interindividual variability of the parame-
ters measured and therefore the lack of statistical power.
The ‘continual reassessment method’ has been used in sev-
eral instances in children. This method allocates doses
sequential to groups of patients. The first group is treated
with the first dose level, whereas dose levels for the subse-
quent groups are determined according to the model
estimates of the dose–efficacy and dose–safety relation-
ships.[36,37] The implications of traditional approaches vs
model-based data analysis for antidepressant drugs were
evaluated by Santen et al.[38,39]
Staggered dose escalation
If there is uncertainty about the safety profile of a medicinal
product, one can start exposing patients to lower doses first
before progressing to higher doses. In this type of study,
one starts with one group of patients (often referred to as a
cohort) and assigns them to a low-dose treatment, during
which the group is observed for some period of time. If no
safety issues are encountered, a new group of patients can
be enrolled and assigned to a higher dose. This process is
repeated until the clinical response is achieved or the maxi-
mum tolerated dose is reached. This design increases
patient safety because you can start by exposing a small
number of patients to the lowest dose possible, which
might discriminate drug response from baseline or control
treatment. By doing so, one mitigates risk by limiting both
the initial number of patients and the exposure of each
patient to study drug. As indicated above, control partici-
pants can be included along with each cohort if the objec-
tive is to compare efficacy with standard of care or other
reference treatment.[33]
Intrapatient dose titration
In a dose titration study, titration is aimed at achieving a
predefined clinical response or maximum tolerated dose
within a patient. This means that each patient will start at a
low dose and receive an incrementally higher dose until a
predefined clinical response or maximum tolerated dose is
reached. Dose titration studies work well in chronic condi-
tions where a drug will be used for a long period of time,
and where it is likely that significant differences will be seen
in the way each patient reacts. Epilepsy is a good example
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of a condition where dose titration is useful.[40] There is
considerable variability in how individual patients respond
to antiepileptic products, and with titrating the dose, one
can tailor treatment with lower doses to patients who are
more responsive to treatment and higher doses to those
who do not respond optimally to the same dose level.
Whereas mainstream data analysis in efficacy trials in
adults relies primarily on treatment comparisons, as
assessed by hypothesis testing (e.g. ANOVA), paediatric
dose-finding studies can benefit enormously from a model-
based approach, in which treatment effects are not esti-
mated primarily based on pairwise comparisons, but by
PKPD parameter estimates. Among the many advantages,
PKPD modelling[19] of dose-finding data allows effective
separation of the variability in response associated with dif-
ferences in drug exposure from other factors known to
cause variation in response. Moreover, data analysis can be
complemented by simulations, including scenarios which
expand the population characteristics to include character-
istics of virtual participants who were not included in the
empirical study, providing insight into the implications of
the dose and response across the overall target population.
Another potential benefit of the use of model-based
approaches (using statistical models for predicting the
effect and efficacy of a drug) is the possibility of eliminating
the need for additional data, thereby avoiding the exposure
of children to unnecessary experimental protocol proce-
dures. In contrast to traditional (descriptive) experimental
protocols, the use of modelling does not limit to summaris-
ing the experimental variables. It relies on the estimation of
parameters, which describe either the disposition (e.g.
clearance, distribution volume) or PKPD relationships (e.g.
potency) as the basis for extrapolation and prediction of
drug exposure and response in a new patient or group of
patients, taking into account individual characteristics and
variability in drug PK or PD parameters. Given that
assumptions can be made about the magnitude of the
changes associated with growth and maturation, mathe-
matical functions exist that allow for scaling of model
parameters. For instance, volume of distribution and clear-
ance are known to change with body weight. Using allo-
metric scaling, it is possible to predict how volume
decreases as body weight becomes smaller. Examples where
adult data have been used to support paediatric dose selec-
tion include the work performed by Avramis et al.[41] and
Piana et al.[23]
In addition, population PK and PKPD models allow for
the identification of additional covariate effects, including
demographic and clinical factors, such as creatinine clear-
ance. Evidence of the influence of such covariates on PK or
PKPD relationships can be used to predict the impact of
overall variability on drug exposure and treatment
response. Most importantly, the parameter estimates
obtained by extrapolation can be directly used as the basis
for dosing recommendations.[42,43]
One can also characterise the effect of demographic and
clinical factors on pharmacokinetics and discriminate them
from factors that influence the variability in pharmacody-
namics, for example disease severity or baseline conditions.
This stepwise approach is often referred to in specialised lit-
erature as hierarchical modelling and has the main advan-
tage of describing both identifiable and non-identifiable
sources of variability. Each ‘variability’ component is
expressed in a hierarchical model as a different parameter.
Identifiable sources of variability are converted into covari-
ate factors during the analysis, whereas non-identifiable
sources are expressed as statistical distributions. Variability,
in this context, is typically split into between-patient vari-
ability, between-occasion variability (within the same
patient on different occasions during the course of treat-
ment) and residual variability in the measurements.[22] The
implementation of this type of analysis can be performed
using different techniques and software programs. The
most commonly used software for population PK and
PKPD modelling is NONMEM (Icon Development Plc,
South County Business Park, Leopardstown Dublin 18,
Ireland). However, other tools exist that can be used to
support the development of nonlinear mixed-effects mod-
elling including, for example, SAS, Monolix, USC*PAC,
MATLAB and ADAPT.[44,45]
In addition to the advantages relative to the methodolog-
ical aspects described above, the use of a model-based
approach allows one to take into account additional chal-
lenges that are faced when collecting and interpreting pae-
diatric data. For instance, it is possible to consider a more
mechanistic approach through incorporation of physiologi-
cally based pharmacokinetic models, which are able to fac-
tor in the contribution of maturation processes in drug
disposition in very young children.
In the era of evidence-based medicine, RCTs remain the
best known approach for the evaluation of efficacy. The
main difference between PKPD studies or dose-finding
studies and randomised efficacy trials is the type of infor-
mation that is generated and the objective of the study. In a
typical RCT, the main objective is to establish the statistical
significance of the mean difference in outcomes between
the intervention groups. The entire study design is aimed at
minimising variability or ‘noise’ around this ‘signal’. In a
PKPD study, on the other hand, the main objective is to
establish how response changes with varying exposure and
whenever possible identify the causes or sources of within-
and between-patient variability. In this respect, patient
characteristics such as age, renal function, maturation sta-
tus and disease severity can all play an important role and
lead to biased estimates of the exposure–response curve, if
not adjusted for. Basically, this difference can be observed
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as a variation on the distinction in two (psychological) sci-
entific paradigms that were described by Cronbach in
1957,[46] that is (1) the correlational approach, in which the
investigator uses variation between patients to study the
correlation with the determinants of this variation, and (2)
the experimental approach, where the investigator attempts
to measure change due to an intervention (the signal) with
as much precision (as little noise) as possible.
The ‘learning-confirming’ paradigm proposed by Shei-
ner,[47] which has been acknowledged by the FDA as an
important step to establish exposure–response and support
dose rationale, enables optimisation of the process to learn
about exposure–response relationship if knowledge cannot
be extrapolated from adult studies.
Information needed for the planning of a
dose-finding study, and how this can be
obtained
The following provides basic information on the elements
that should be considered when planning a dose-finding
study. We want to emphasise that the first step when plan-
ning such a study is to consult all the important players:
clinicians, nurses, patients/parents, pharmacists, geneticists
and clinical pharmacologists with modelling expertise.
Obviously, the exact composition of the team will depend
on the investigational product. The clinical pharmacologist
can advise on the design of the study and minimisation of
patient samples. The GRiP initiative offers an educational
programme for paediatric investigators interested in this
type of research.[48]
One of the consequences of the difference between typi-
cal RCTs for the evaluation of efficacy and PKPD studies is
the different emphasis, that is from statistical power and
sample size for hypothesis testing to parameter accuracy
and precision for model fitting. The precision of PK and
exposure–response parameters is critical in the sample size
calculation for paediatric PKPD studies. Prior knowledge
of the disease, exposure, and response from adults and
other relevant paediatric data, such as that related to vari-
ability, can be used to derive the optimal sample size for
ensuring precise parameter estimation. The investigators
should account for all potential sources of variability,
including interpatient and intrapatient variability, and dif-
ferences between the adult and paediatric populations in
the final selection of the sample size for each age group.
Simulations can play a key role in that process, as variabil-
ity is not considered to be only random. Moreover, it is the
evidence of an exposure–response relationship that should
define the success of the trial, not the statistical significance
of eventual differences between treatment arms.
The distinct age groups to be studied should be chosen
based upon what is known about the prevalence and
incidence of the disease, taking into account the role of
developmental growth, maturation processes and ontogeny,
all of which can affect pharmacokinetics, pharmacodynam-
ics and the safety profile of a drug.
If the drug is intended for use in newborn infants, the
paediatric study plan should specify whether premature or
small-for-gestational-age infants will be included in the
study population. Given the influence of different factors
on pharmacokinetic and pharmacodynamic variability, it is
important to ensure all relevant information is captured for
each patient, for instance gestational age and serum crea-
tinine or cystatin C for preterm infants, birthweight and
actual weight for infants and toddlers.
In 2012, the FDA discussed a proposal, ultimately
rejected by the Advisory Committee, for a sample size stan-
dard for paediatric pharmacokinetic studies, which stated
that a study had to be powered with at least 80% to target a
confidence interval with no more than 20% relative stan-
dard error in the pharmacokinetic parameter estimates,[49]
but with nonlinear mixed-effects methods, also known as
population approach, sample size is not the only relevant
aspect. Sample size calculations are well explained by
Roberts et al.,[50] who also describe the software programs
available for this purpose. Although these authors show
that for every situation an ‘optimal’ sample size and study
design can and should be determined, they seem to over-
look important feasibility issues that need to be considered,
especially when dealing with newborns and toddlers.
Important for paediatricians is that PKPD studies do not
necessarily follow the same design route as classical RCTs.
PKPD studies are designed with the objective of learning
about the appropriate dose, and hence must not follow the
logic of the classical study that aims to determine the differ-
ence in outcome between groups.
Non-compartmental analysis based on rich PK sampling
has been common practice for a large number of paediatric
trials. The use of frequent blood sampling has led to impor-
tant ethical and practical challenges in the implementation
of clinical trials. This situation can be improved by better
understanding of paediatricians about the value of model-
based approaches. Population PK and PKPD modelling
analysis based on sparse PK sampling can achieve sufficient
precision for the characterisation of PK and PKPD parame-
ters.[49]
From the above, it is evident that the number of blood
samples collected in the clinical pharmacology study is as
critical as the number of patients available and the dose
levels under consideration for the study.[18,50] Tools have
been developed in statistical research to provide insight
into the contribution of (individual) input data to the over-
all precision of parameter estimates.[51] These techniques
can become powerful when combined with new sampling
techniques such as dried blood spots or microsampling,
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particularly in special paediatric patient groups such as
neonates. Clinical study simulations can be further imple-
mented to illustrate the impact of different sampling and
design scenarios, thereby justifying the proposed sampling
scheme and overall protocol design. On the other hand,
one should also consider that additional sampling for drug
or metabolite may be required if more than efficacy is to be
established. Opportunistic (ad hoc) sampling should be
considered when acute adverse events occur.
One last keynote on the advantages of PKPD studies is
the possibility of establishing the clinical relevance of
covariate factors known to affect pharmacokinetics or
pharmacodynamics in children. Therefore, attention must
be given to the way information is collected in these kinds
of trials, especially the so-called time-varying covariates,
such as age, body weight, BSA and many biochemical and
haematological parameters (clinical laboratories) which
may be closely linked to organ function and reflect differ-
ences in drug disposition or pharmacodynamics. In addi-
tion, information regarding the onset of disease,
phenotype, genotype, time since diagnosis, concomitant
and recent drug therapy should also be considered as rele-
vant factors in some diseases. It should be noted that some
covariate factors will be relevant only in a subgroup of
patients, for example organ maturation, whereas others can
affect the whole patient population.
Conclusions
Paediatricians can and should perform investigator-
initiated clinical pharmacological research in children as
there are many gaps in the knowledge about drugs used for
children. To develop rational, patient-tailored dosing
schemes, population PKPD studies in children and infants
are needed. The emergence of new laboratory techniques
and statistical tools allows for the analysis of sparse and
unbalanced data and has increased the possibilities to per-
form (observational) PKPD studies in the paediatric clinic.
To improve the quality of future paediatric PKPD investi-
gations, and to prevent the conduct of paediatric RCTs that
are doomed to fail because of inadequate dosing, the expe-
rience and knowledge about these tools is shared in this
study. If performed well, the results of these studies will
contribute to the evidence base underlying clinical guideli-
nes and regulatory decisions concerning labelling adjust-
ments.
In contrast to the design of RCTs for the assessment of
efficacy, in which the aim is to minimise the signal-to-noise
ratio, studies aimed at the characterisation of the exposure–
response curve and subsequent dose selection of a drug
need to consider the sources of variation in the target pop-
ulation. This means that in the design of a paediatric PKPD
study, intrinsic factors determining variability in drug
exposure and response, such as age, weight and gender, will
have to be accounted for carefully to maximise the amount
of information gathered from the smallest possible number
of participating children.
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